Anticoagulation.
This review of anticoagulation discusses not only drugs that inhibit the formation of blood clots but also drugs that induce clot lysis. It includes warfarin, heparin and streptokinase as well as newer agents such as low molecular weight (LMW) heparins and recombinant tissue plasminogen activator (r-tPA).
Chong
B H
BH
Haematology Department, Prince of Wales Hospital.
D000368:Aged; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D004347:Drug Interactions; D006493:Heparin / Q000009:adverse effects / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006496:Heparinoids / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy; D011655:Pulmonary Embolism / Q000188:drug therapy; D013300:Streptokinase / Q000009:adverse effects / Q000627:therapeutic use; D015912:Thrombolytic Therapy; D013924:Thrombophlebitis / Q000188:drug therapy; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use; D014859:Warfarin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use
D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D006496:Heparinoids; D014859:Warfarin; D006493:Heparin; D013300:Streptokinase; D010959:Tissue Plasminogen Activator